Stevia First Corp. Spring 2015

Safe Harbor Statement

2

This presentation and our commentary and responses to your questions may contain forward-looking statements, including

comments concerning product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of our technology by potential

corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from

those set forth in our regulatory filings from time to time.

3

We are facing global epidemics of diabetes and obesity.

What We Do Identify “critical unmet needs” that can revolutionize the food &

nutrition industries for the better

4

Reduce sugar overuse by solving stevia supply issues

•Premier global supplier of stevia

•R&D – Enzyme enhancement for increased global supply

•R&D - Next-gen sweeteners that are more “sugar-like”

Prevent diabetes and obesity with GRAS geroprotectors

•R&D – GRAS nutraceutical and functional food ingredients based on energy and nutrient sensing pathways, including ones that affect lifespan and addiction, and that mimic or enhance the effects of exercise and fasting

We intend to make dramatically healthier food and

nutritional products affordable enough for everyone

5

Credit Suisse, “Sugar: Consumption at a Crossroads”, September 2013

Key conclusion: “The most likely outcome over the next 5-10 years will be a significant reduction in sugar consumption and a marked increase in the role played by high-intensity natural sweeteners in foods and beverages.”

Twin global epidemics of diabetes and obesity “…30%–40% of healthcare expenditures in the USA go to help address issues that are closely tied to the excess consumption of sugar.”

Sugar: Consumption at a Crossroads Sugar reduction is imminent and an inevitable trend

Morgan Stanley, “The Bitter Aftertaste of Sugar”, March 2015

Market Opportunity Stevia has taken off but multinationals need far more supply

6

Natural

Sweeteners

(sugar, honey,)

Stevia

natural

zero calories

Artificial

Sweeteners

(aspartame, saccharin, etc.)

The “holy grail of sweeteners” has been delivering on numerous fronts for multinationals enabling commercial successes like Truvia and VitaminWater Zero

SF is aiming to develop key enabling production technologies to fuel global stevia product launches by multinationals already invested heavily in stevia product lines

Featured on:

Agri-Bio Supply Innovations Mechanized agriculture combined with enzymatic bioprocessing could

more than double global output of Reb A

7

Enzyme Bioprocessing

High-purity Reb A at higher yields, lower cost

(RA97 or greater, $90K-$100K per metric ton)

7

Traditional Solvent Purification Reb A leaf extract purification - Discards Reb A precursor

Stevioside as a “byproduct” - Loss of Reb A from solvent

crystallization purification process

“Finishing what the leaf started” -Reb A precursor Stevioside (red) is

no longer a byproduct - 2 times or more Reb A per ton

of leaf or acre - 10 times or more Reb D or Reb

M next-gen stevia sweeteners

Bales of stevia leaf Labor-intensive leaf

production is more than 70% of traditional costs

Intellectual Property

Patents and patent applications related to production of steviol and steviol glycosides through microbial fermentation and biosynthesis

Patent application covering stevia enzymatic enhancement methods

Patent application covering novel agricultural production methods using drone technology and LED photoperiod interruption

Product Commercialization Stevia First is poised to become a premier global stevia supplier and

the only producer in North America

9

August 2014 definitive agreements with Qualipride provide exclusive terms for Stevia First to take over stevia distribution business with more than 350 tons of stevia exports last year and access through partners to more than 1,000 metric tons of annual high-purity stevia production capacity, more than 100 tons of stevia extract in stock and available immediately

Stevia First has exclusive rights to modern stevia extraction and refining technologies outside China and aims to soon begin construction on first North American stevia production facilities

Seed and cuttings for 10,000

hectares

200

hectares

400

hectares 3,000

hectares

4,000

hectares

300 MT 200 MT

400 hectares

(California)

Proposed Capacity Current Capacity

Seed

Leaf

Extract

Refine (or Enzyme Enhancement)

Sales Supply Chain: >1,000 metric tons High-purity Reb A

1,000+ MT 1,000 MT 150+ MT

(California)

500 MT 500 MT 500 MT 50+ MT

(California)

Qualipride -> Stevia First

SF’s Supply Chain more than a decade of experience controlling

stevia quality and price from “soil-to-sale”

Financial Highlights opportunity to become cash flow positive through new operations

in 2015 even while investing heavily in long-term R&D

11

New businesses could each fund entire R&D operations and corporate overhead upon launch and SF reaching desired margins and scale

Market leader Purecircle (LON: PURE) has valuation of more than US$1 billion (March 2015) with fully invested supply chain capable of delivering 2,800 metric tons of high purity stevia as of their 2013 annual report.

Stevia Business Operations Product

Margin Scale (MT)

Initial Operations

Resale & Distribution RA60 >10% 450 5%-20% >1,000

Enzyme Enhancement RA97 >18% 150 35%-60% >1,000

U.S. Expansion

California Extraction RA60 >30% 150 15%-35% 150

California Enzyme Enhancement RA97 >40% 200 50%-75% 200

Breakeven Metrics Planned

Capacity (MT)

Potential

Margins

Leadership building a growth engine

12

Anthony Maida, PhD, MBA, Director, Chair of Audit Committee

Senior Vice President, Clinical Research, Northwest Bio

MBA, MA in Toxicology, PhD in Immunology, Family farm management experience

Robert Brooke, CEO & Co-founder

Ex-hedge fund analyst at BCA for over 50 direct healthcare investments

Experienced biotech entrepreneur, Founder of Genesis, nka Lion Biotech, Co-Founder of Intervene Immune

B.S. in Electrical Eng., Georgia Tech; M.S. in Biomedical Eng., UCLA

Avtar Dhillon, MD,

Chairman & Co-founder

Chairman, Inovio Pharmaceuticals, Oncosec Medical, and Arch Therapeutics

Capital raises in public markets > $200M over last 10 years

Former venture capitalist and family medicine physician for > 10 years

Jeremiah Mann, PhD, Sr. Agronomist, VP of Ops

Ex-USDA Conservation Agronomist at California’s Natural Resource Conservation Service

PhD in Horticulture and Agronomy, Univ of California Davis

Richard McKilligan, JD, MBA, Controller

Ex-Morgan, Lewis, & Bockius LLP, State Bars in CA and NY, CPA (inactive)

JD from Cornell, MBA from Univ of Chicago, BS in Accounting from Univ of Illinois

13

Our R&D Approach employing breakthrough technologies and a multidisciplinary team of

more than 20 researchers, including full-time staff and technical advisors

Novel, Patentable Solutions

Bioinformatics, and our “AI Scientist” Platform

Translational medicine, “bench-to-bedside”

Horticulture, agronomy, and the plant sciences

Fermentation and bioprocessing

Breakthrough

technologies

(in hands of our multidisciplinary

R&D team)

Emerging Role of Geroprotectors This new class of molecules influence the underlying cause of

metabolic disorder, diabetes, and obesity, rather than the symptoms

14

Metformin

Products that mimic the health benefits of fasting and exercise are becoming known, related to nutrient sensing pathways (AMPK, Sirtuins, and many more…)

Insulin

Sirtuins AMPK “Exercise-in-a-bottle”

Rapamycin mTOR

“Junk food vaccine”

FOXO3

R&D:“AI Scientist” Platform Proven AI bioinformatics team for diverse R&D needs

including geroprotector discovery with machine learning

15

Reanalyze genomics data when traditional statistics packages have not

worked.

Find novel combination treatments when other groups found only

statistical noise.

“…we’re still swimming in a sea of ignorance about how all these pathways and targets are integrated and how we can

intervene in them safely.” – Buck Institute researcher, December 2014

Nutraceutical Development Novel geroprotectors have broad commercial potential as

nutraceuticals, functional food ingredients, or even pharmaceuticals

16

Pharma gene therapy collaboration

March 2015

Food & Nutrition Products SF Corp. sells and develops food & nutrition products

along with complementary research tools

17

- Commercial: Research products, Provider to key research universities, further distributed through international distribution network and open-source communities

- Commercial: Stevia, Becoming a large global supplier - R&D: Next-gen stevia, Proprietary bioprocessing, and building

first vertically-integrated North American facilities - R&D: Geroprotectors, Developing proprietary functional

ingredients for prevention of metabolic disorder

CORE PRODUCTS, and related intellectual property for

production and use

RESEARCH PRODUCTS, in cutting-edge fields, used to enable us

to work with partners and speed progress on high-priority projects

Do

es a

n e

ffec

tive

pro

du

ct s

eem

po

ssib

le y

et?

Trading Snapshot (Ticker: STVF) an ag-biotech company addressing global diabetes and obesity

epidemics with mass market food and nutrition products

18

$0.36 share price ~$25M market cap

Trading data as of March 2015

~202K avg. volume (3m)

Shareholder base: 8,351 shareholders Recent financing: $1.5M warrants

Shares outstanding: 72,928,915 shares Average volume: 202,484 shares

52 Week Range: $0.29-$0.48

Corporate Profile a publicly-traded ag-biotech company

headquartered in Yuba City, California

(OTCQB: STVF)

19

Stevia First Corp. 5225 Carlson Road

Yuba City, CA 95993 (530) 231-7800

info@stevia-first.com www.steviafirst.com

Fiscal Year End:

March 31st

Auditors: Weinberg & Co.

Los Angeles Office

Securities Counsel: Morrison & Foerster

San Diego Office

Industry Activity & Milestones SF operates in dynamic industries with multinationals poised for change

20

Mar ‘13

2Q‘13

Coca-Cola reformulates Sprite in UK with stevia; launches an anti-obesity ad campaign

Company demonstrates production through enzyme enhancement

Business Development (ongoing) Technology partnerships Commercial partnerships

New licensing opportunities

INTRINSIC EXTRINSIC

4Q’13

SF’s initial Tasting Event including enzyme enhanced stevia product

3Q ‘14

2Q ‘15

Accelerates stevia commercialization through Qualipride relationship

Announcement of Geroprotector Discovery & Testing Results

World Health Organization cuts daily sugar intake guidance to 5% of calories, less than a single 12-oz can of soda, Mexico imposes sugar tax

1Q’14

Announcement of Geroprotector Intellectual Property Filings

Google reported to buy DeepMind, an AI startup for $400M; Google Calico and Craig Venter’s HLI operate with focus on longevity genes

Morgan Stanley issues report on sugar curtailing economic growth; Indian government asks PepsiCo to reformulate

Coke Life and Pepsi True are launched, the start of the stevia cola wars

1Q ‘15

Major Sales Contracts or Strategic Partnerships for Stevia

Partnerships for Diabetes & Obesity Clinical Interventions

Geroprotector program announced; BioViva pharma collaboration

Investment Highlights

Poised to become a premier global stevia supplier and capitalize on the lucrative sweetener market worth over $55 billion

Proven and dedicated management

Development of novel food, nutrition, and pharma products (“geroprotectors”) related to diabetes and obesity

Multiple patents and patent applications related to core technologies including stevia bioprocessing